Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for prevention and treatment of radiation-induced oral mucositis in nasopharyngeal carcinoma
ChiCTR2600132171Phase 3Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pirfenidone in stomatitis and Radiation-induced oropharyngeal mucositis (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Incidence of grade 3-5 radiation-induced oral or oropharyngeal mucositis. Started May 2025; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
stomatitisRadiation-induced oropharyngeal mucositis
Beyond the preview
Go deeper on ChiCTR2600132171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132171.